Ease: Ezetimibe Add-on to Statin for Effectiveness Trail

2006 ◽  
Vol 4 (1) ◽  
pp. 32-35
Author(s):  
Linda Brokes
Keyword(s):  
National Cholesterol Education Program ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cholesterol Absorption ◽  
Adult Treatment ◽  
Adult Treatment Panel ◽  
Community Based ◽  
Cholesterol Absorption Inhibitor ◽  
Additional Reduction

Results from the largest community-based clinical trial to date, involving more than 3000 patients, has shown that adding the cholesterol absorption inhibitor ezetimibe to ongoing stable statin therapy in patients with hypercholesterolemia produces a significant additional reduction in low-density lipoprotein (LDL)- cholesterol compared with adding a placebo.[1] In addition, more patients who added ezetimibe achieved their National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) If LDL-cholesterol targets. The Ezetimibe Add-on to Statin for Effectiveness (EASE) trial included a total of 3030 patients on a stable dose of a statin but not yet at their NCEP ATP III LDLcholesterel goal,[2]

scholarly journals Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Akshyaya Pradhan ◽  
Monika Bhandari ◽  
Rishi Sethi
Keyword(s):  
Statin Therapy ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cholesterol Absorption ◽  
Cardiovascular Outcomes ◽  
Current Evidence ◽  
High Dose ◽  
Residual Cardiovascular Risk ◽  
Intestinal Cholesterol Absorption ◽  
Cholesterol Absorption Inhibitor

Low-density lipoprotein lowering with statins has convincingly and consistently proven to reduce cardiovascular events in both primary and secondary prevention. However, despite high-dose statin therapy, residual cardiovascular risk remains and many patients also do not tolerate statins. Ezetimibe was initially projected as a frontline alternative to statin. It is an intestinal cholesterol absorption inhibitor with modest LDL lowering effects. But, major studies failed to demonstrate any beneficial effect of CV outcomes, and the drug was relegated to oblivion. IMPROVE-IT, a contemporary, large, and well-designed trial, unequivocally demonstrated reduction in CV outcomes with ezetimibe when added to statin therapy. The benefits are seen in both sexes, elderly, CKD, diabetes mellitus, and in patients with prior CABG. It also reduces biomarkers and induces plaque regression like statins. The drug has now established itself as an add-on therapy to statin when monotherapy fails to achieve LDL goals and when it is not tolerated. The combination therapy has excellent safety and efficacy record. It has now been endorsed by major guidelines too in management of dyslipidemia. Yes, ezetimibe can indeed improve cardiovascular outcomes!

scholarly journals NON-PHARMACOLOGICAL THERAPY OF HYPERLIPIDAEMIA

2003 ◽  
Vol 41 (142) ◽  
pp. 356-360
Author(s):  
Urgra Narayan Pathak ◽  
D L Gurubacharya
Keyword(s):  
National Cholesterol Education Program ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Pharmacological Therapy ◽  
Blood Cholesterol ◽  
Low Density ◽  
First Line ◽  
Factors Associated

Hyperlipidaemia is one of the major contributors to atherosclerosis and CoronaryHeart Disease (CHD) in our society. Numerous clinical and epidemiological studieshave shown repeatedly that an elevated blood cholesterol level is one of the majormodifiable risk factors associated with the development of CHD. In particular, thesestudies have demonstrated that low- density lipoprotein (LDL) cholesterol is theprimary lipoprotein mediating atherosclerosis. Non-pharmacological therapy especiallydietary therapy and exercise remains the first line of treatment in hyperlipidaemia,with pharmacotherapy reserved for use in patients at high risk of coronary heartdisease or patients who do not respond to non-pharmacological therapyKey Words: Hyperlipidaemia, LDL Cholesterol, HDL Cholesterol, coronary HeartDisease (CHD), Atherosclerosis, National Cholesterol Education Program (NCEP)

Sign in / Sign up

Export Citation Format

Share Document